Ashish Saxena, PhD, MD

Highlights

1
Clinical lung cancer · 2024
PRPeyman Razavi ASAshish Saxena
PMID: 39674767DOISenior author
2
Scientific reports · 2021
ASAshish Saxena KGKazunori Gomi RGRonald G Crystal
PMID: 33731767PMCID: PMC7969738DOIFirst author18 citations
3
Cancer treatment and research communications · 2026
CAChristine Ann Garcia XKXi Kathy Zhou ASAshish Saxena
PMID: 41576524DOI eCommonsSenior author2 citations

Publications

Funding

Completed grants (1)

Co-I
Communicating the Gist of Prognosis: Giving Information Simply and Transparently ("GIST") in Advanced Cancer
National Institute of Nursing Research · 2019–2022
R21NR018693-02

Clinical research

Active

8 studies

PI
A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients With DLL3-Expressing Tumors Including Small Cell Lung Cancer
PHASE1; PHASE2 · IDEAYA Biosciences · OPEN TO ACCRUAL (as of 2026)
Small-cell Lung Cancer; Neuroendocrine Carcinomas; Solid Tumor Show to Express DLL3
NCT07174583
PI
IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy
PHASE2; PHASE3 · Bristol-Myers Squibb Company · OPEN TO ACCRUAL (as of 2026)
Non-Small Cell Lung Cancer
NCT07100080
PI
A Phase III, Multisite, Double-blinded Randomized Trial of BNT327 in Combination With Chemotherapy (Etoposide/Carboplatin) Compared to Atezolizumab in Combination With Chemotherapy (Etoposide/Carboplatin) in Participants With First-line Extensive-stage Small-cell Lung Cancer
PHASE3 · BioNTech SE · OPEN TO ACCRUAL (as of 2026)
Extensive-stage Small-cell Lung Cancer
NCT06712355
PI
Immune Checkpoint Inhibitor Arthritis and Other Autoimmune Side Effects/Adverse Events: Validating a Claims Data Definition Through Medical Record Review
Hospital for Special Surgery · OPEN TO ACCRUAL (as of 2026)
PI
A Phase III, Open-label, Randomised Study of Osimertinib With or Without Datopotamab Deruxtecan (Dato-DXd), as First-line Treatment in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer
PHASE3 · AstraZeneca, PLC · OPEN TO ACCRUAL (as of 2025)
Non-small Cell Lung Cancer
NCT06350097
PI
A Phase 1/2, First in Human, Dose Escalation and Dose Expansion Study of BHV-1510 (Previously PBI-410) as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Tumors
PHASE1; PHASE2 · Biohaven Pharmaceuticals Inc., · OPEN TO ACCRUAL (as of 2025)
Solid Tumor
NCT06384807
PI
Molecular Profiling of Sequential Samples of Thymomas
Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2021)
PI
A Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 as Monotherapy and in Combination With Pembrolizumab in Subjects With Solid Tumors or Lymphoma
PHASE1; PHASE2 · VM Oncology, llc · OPEN TO ACCRUAL (as of 2021)
Head and Neck Carcinoma; Adenoid Cystic Carcinoma; Lung Cancer; Non-Small Cell Lung Cancer; Pancreatic Cancer; Mesothelioma; Esophageal Cancer; Any Solid Tumors Progressed After a Prior Immunotherapy; Head and Neck Squamous Cell Carcinoma; Head and Neck Squamous Cell Carcinoma HNSCC; Salivary Gland Carcinomas; Head and Neck Cancers - Salivary Gland; Head and Neck Cancers - Nasopharyngeal; Head and Neck Cancers - Throat; Small Cell Lung Cancer ( SCLC ); Lung Cancer (Locally Advanced or Metastatic); Head and Neck Cancers - Tonsils; Head and Neck Cancers Hypopharynx; Head and Neck Cancers Larynx; Head and Neck Cancers Lip; Head and Neck Cancers Nasopharynx; Head and Neck Cancers Oral Cavity; Head and Neck Cancers; Head and Neck Cancers Oropharynx; Head and Neck Cancers Trachea
NCT03556228

Completed & closed trials (14)

PI
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
PHASE1 · IDEAYA Biosciences · IRB STUDY CLOSURE (as of 2026)
Advanced or Metastatic Solid Tumors; Breast Cancer; Ovarian Cancer; Prostate Cancer; Endometrial Cancer; Colorectal Cancer; Head and Neck Cancers; Extensive Stage Small Cell Lung Cancer (ES-SCLC); NSCLC
NCT05787587
PI
A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
PHASE1 · National Cancer Institute · CLOSED TO ACCRUAL (as of 2026)
Autoimmune Disease; Crohn Disease; Dermatomyositis; Hematopoietic and Lymphoid Cell Neoplasm; Inflammatory Bowel Disease; Malignant Solid Neoplasm; Multiple Sclerosis; Psoriasis; Psoriatic Arthritis; Rheumatoid Arthritis; Sjogren Syndrome; Systemic Lupus Erythematosus; Systemic Scleroderma; Ulcerative Colitis
NCT03816345
PI
A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer
PHASE2 · Eikon Therapeutics INC · CLOSED TO ACCRUAL (as of 2026)
NSCLC
NCT06246110
PI
A Phase 2 Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors
PHASE2 · Gilead Sciences, Inc. · IRB STUDY CLOSURE (as of 2025)
Metastatic Solid Tumor
NCT03964727
PI
A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer
PHASE2 · National Cancer Institute · IRB STUDY CLOSURE (as of 2025)
Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Refractory Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8
NCT03600701
PI
A Randomized Phase II Trial of Carboplatin-Paclitaxel With or Without Ramucirumab in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma
PHASE2 · Southwest Oncology Group · IRB STUDY CLOSURE (as of 2025)
Locally Advanced Thymic Carcinoma; Metastatic Thymic Carcinoma; Recurrent Thymic Carcinoma; Unresectable Thymic Carcinoma
NCT03694002
PI
A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50%
PHASE2 · Regeneron Pharmaceuticals, Inc. · CLOSED TO ACCRUAL (as of 2025)
Advanced Non-Small Cell Lung Cancer
NCT05557591
PI
An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations
PHASE2 · Gilead Sciences, Inc. · IRB STUDY CLOSURE (as of 2024)
Non-small Cell Lung Cancer
NCT05186974
PI
Phase II Trial of Platinum-Etoposide Chemotherapy and Durvalumab (MEDI4736) With Sub-Ablative SBRT in Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer
PHASE2 · Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2023)
Small-cell Lung Cancer
NCT04951115
PI
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
PHASE2 · Alliance for Clinical Trials in Oncology · CLOSED TO ACCRUAL (as of 2023)
Metastatic Lung Adenocarcinoma; Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8
NCT04533451
PI
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
PHASE2 · Calithera Biosciences, Inc. · IRB STUDY CLOSURE (as of 2022)
Non-Small Cell Lung Cancer; Non-squamous Non-small-cell Lung Cancer; Non-Squamous Non-Small Cell Neoplasm of Lung; KEAP1 Gene Mutation; NRF2 Gene Mutation; NFE2L2 Gene Mutation
NCT04265534
PI
A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer
PHASE2 · Array BioPharma Inc. · IRB STUDY CLOSURE (as of 2021)
Non-small Cell Lung Cancer
NCT03915951
PI
A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab (MEDI4736) Alone or in Combination With Novel Agents in Subjects With Locally Advanced, Unresectable (Stage III) Non-small Cell Lung Cancer (COAST)
PHASE2 · MedImmune, LLC · IRB STUDY CLOSURE (as of 2021)
Stage III Non-small Cell Lung Cancer; Unresectable
NCT03822351
PI
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
PHASE3 · Alliance for Clinical Trials in Oncology · CLOSED TO ACCRUAL (as of 2021)
Lung Non-Squamous Non-Small Cell Carcinoma; Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIA Lung Non-Small Cell Carcinoma AJCC v7; Stage IIB Lung Non-Small Cell Carcinoma AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7
NCT02193282

Media highlights

Ask About Clinical Trials On Day One
Trinity Journal · September 23, 2026
Life-Saving Questions For Lung Cancer Patients
Business First AM · September 22, 2026
Kirkwood Cancer Survivor Urges Patients To Ask About Trials
KTVI-TV (St. Louis, MO) · September 16, 2026
New Research Is Giving Hope To Patients With Small Cell Lung Cancer
WVON 1690AM (Chicago, IL) · September 15, 2026

External relationships

Advisory/Scientific Board Member

BMS · Genentech, Inc.

Other Interest

BMS · Galvanize Therapeutics, Inc. · Johnson & Johnson

Other

AstraZeneca Pharmaceuticals LP · Galvanize Therapeutics, Inc. · Johnson & Johnson